Aprea Therapeutics, Inc.

APRE · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$2,972-$3,239-$3,933-$2,895
Dep. & Amort.$5$5$5$5
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$137$119$126
Change in WC-$339-$63$126-$708
Other Non-Cash$42$29$52-$39
Operating Cash Flow-$3,263-$3,131-$3,631-$3,511
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow$0$0$0$0
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$371$400$56$141
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0-$15$0-$6
Financing Cash Flow$371$385$56$134
Forex Effect$78$3$1-$25
Net Chg. in Cash-$2,814-$2,743-$3,574-$3,401
Supplemental Information
Beg. Cash$16,532$19,316$22,890$26,291
End Cash$13,718$16,573$19,316$22,890
Free Cash Flow-$3,263-$3,131-$3,631-$3,511
Aprea Therapeutics, Inc. (APRE) Financial Statements & Key Stats | AlphaPilot